Notice for cedazuridine and decitabine (Taiho Pharma Oceania Pty Ltd)
Active ingredients
cedazuridine and decitabine
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
tablet
Indication
INQOVI 35/100 is indicated as a combination therapy with venetoclax for the treatment of acute myeloid leukaemia (AML)
Therapeutic area
Haematology